• Department of Endocrinology, the Second People's Hospital of Yibin City, Yibin, Sichuan 644000, P. R. China;
Export PDF Favorites Scan Get Citation

Objective To compare the efficacy of sitagliptin plus glargine insulin versus repaglinide plus glargine insulin in the treatment of Type-2 diabetes mellitus (T2DM). Methods A total of 140 T2DM patients who were inadequately controlled by oral anti-diabetic agents from January 2011 to December 2012 were divided into sitagliptin plus glargine insulin group (observation group) or repaglinide plus glargine insulin group (control group). The duration of treatment was 12 weeks. Fasting blood glucose (FBG), 2h plasma glucose (2hPG), glycated haemoglobin (HbA1c), body max index (BMI) and dose of insulin as well as hypoglycemia events were recorded and analyzed. Results After treatment, FBG, 2hPG, and HbA1c were significantly decreased in both groups (P<0.05). HbA1c targeting rate was 88.3% in the observation group and 87.8% in the control group. Compared with the control group, the observation group used 12.1% less dosage of insulin, and had decreased BMI and low incidence of hypoglycemia. Conclusion Sitagliptin plus glargine insulin can effectively control blood glucose and body weight with low incidence of hypoglycemia and much less insulin dosage under the same HbA1c targeting rate. Sitagliptin plus glargine insulin is a good combination therapy for the treatment of T2DM.

Citation: HUAYan, WUJin-wen, JIANGCheng-xia, LIMei, LIUXin. Clinical Observation of Sitagliptin plus Glargine Insulin versus Repaglinide plus Glargine Insulin in the Treatment of Type-2 Diabetes. West China Medical Journal, 2014, 29(8): 1429-1431. doi: 10.7507/1002-0179.20140440 Copy

  • Previous Article

    依托城乡对口支援建立绵阳地区组织化卒中管理模式
  • Next Article

    Efficacy of Combination of Pancreatic Kinionogenase and Mecobalamin on Diabetic Peripheral Neuropathy